Senti Biosciences (SNTI) Common Equity (2021 - 2025)

Senti Biosciences has reported Common Equity for 5 years, with the latest figure at $5.6 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 78.21% year-over-year to $5.6 million; the trailing twelve-month figure through Dec 2025 stood at $5.6 million (down 78.21% YoY), and the FY2025 full-year result was $5.6 million, down 78.21% from the prior year.
• Common Equity for Q4 2025 stood at $5.6 million, down from $8.1 million in the prior quarter.
• The five-year high for Common Equity was $154.3 million in Q2 2022, with the low at -$121.8 million in Q1 2022.
• Average Common Equity over 5 years is $24.8 million, with a median of $31.8 million recorded in 2024.
• Year-over-year, Common Equity soared 270.2% in 2022 and sank 80.72% in 2024.
• Tracing SNTI's Common Equity over 5 years: stood at -$111.5 million in 2021, then jumped by 214.18% to $127.3 million in 2022, then sank by 47.42% to $66.9 million in 2023, then plunged by 61.67% to $25.6 million in 2024, then tumbled by 78.21% to $5.6 million in 2025.
• The last three Common Equity figures came in at $5.6 million (Q4 2025), $8.1 million (Q3 2025), and $24.7 million (Q2 2025), per Business Quant data.

Peer Comparison